| Xin Wang,Yingying Xie,Guanjun Jing,Fang Yu,Yinghong Ren. The efficacy and safety of thalidomide for treating metastatic breast cancer: a systematic review. Oncol Transl Med, 2020, 6: 98-102. |
| 沙利度胺治疗转移性乳腺癌安全性和有效性的系统评价 |
| The efficacy and safety of thalidomide for treating metastatic breast cancer: a systematic review |
| Received:March 14, 2019 Revised:June 02, 2020 |
| DOI：10.1007/s10330-019-0341-1 |
| 中文关键词: 沙利度胺 转移性乳腺癌 VEGF TNF-a |
| 英文关键词: thalidomide; metastatic breast cancer (MBC); vascular endothelial growth factor (VEGF); tumor necrosis factor-α (TNF-α) |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Xin Wang | 1 Department of Oncology, Shangluo Central Hospital | wx780@163.com | | Yingying Xie | 1 Department of Oncology, Shangluo Central Hospital | | | Guanjun Jing | 1 Department of Oncology, Shangluo Central Hospital | | | Fang Yu | 1 Department of Oncology, Shangluo Central Hospital | | | Yinghong Ren* | 1 Department of Oncology, Shangluo Central Hospital | 452131257@qq.com |
|
| Hits: 9109 |
| Download times: 10357 |
| 中文摘要: |
| 系统评价沙利度胺用于治疗转移性乳腺癌的作用。按照纳入和排除标准总共收集了3项研究的数据信息。总的数据分析研究分析显示不同剂量的沙利度胺治疗晚期转移乳腺癌均未能达到部分缓解或完全缓解。沙利度胺100mg，200mg和400mg不同剂量口服耐受性良好。常见的不良反应包括便秘、嗜睡、疲乏、外周神经异常和口干。总之目前研究数据显示沙利度胺单药治疗转移乳腺的作用有限。 |
| 英文摘要: |
| Objective This systematic review was conducted to investigate the efficacy and safety of thalidomide in
metastatic breast cancer (MBC).
Methods Based on pre-defined inclusion and exclusion criteria, data were independently collected from
different databases by three investigators. Overall, three studies were included.
Results The included studies indicated that no patient achieved a partial or complete response from
different thalidomide dose levels. Thalidomide was well-tolerated at doses of 100 mg, 200 mg, and 400 mg.
In all three studies, common side effects included constipation, somnolence, fatigue, peripheral neuropathy,
and dry mouth. Circulating angiogenic factors were not significantly correlated with disease progression.
Conclusion The available evidence indicates that single-agent thalidomide has little or no activity in
patients with MBC. |
|
View Full Text
Download reader HTML全文 |
| Close |